Controlled colonization of the human gut with a genetically engineered microbial therapeutic
Science · 17.07.2025 · 389 (6757) · 303-308
DOI: 10.1126/science.adu8000 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Science, erschienen am 17.07.2025. Verfasst von Weston R Whitaker und 23 weiteren Autor:innen. Beteiligte Einrichtung: Novome Biotechnologies, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Colon, Gastrointestinal Microbiome, Kidney Calculi, Bacteroidaceae. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Precision microbiome programming for therapeutic applications is limited by challenges in achieving reproducible colonic colonization. Previously, we created an exclusive niche that we used to engraft engineered bacteria into diverse microbiota in mice by using a porphyran prebiotic. Building on this approach, we have now engineered conditional attenuation into a porphyran-utilizing strain of Phocaeicola vulgatus by replacing native essential gene regulation with a porphyran-inducible promoter to allow reversible engraftment. Engineering a five-gene oxalate degradation pathway into the reversibly engrafting strain resulted in a therapeutic candidate that reduced hyperoxaluria, a cause of kidney stones, in preclinical models. Our phase 1/2a clinical trial demonstrated porphyran dose–dependent abundance and reversible engraftment in humans, reduction of oxalate in the urine, and characterized genetic stability challenges to achievinglong-term treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Novome Biotechnologies, South San Francisco, CA, USA.
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
- Chan Zuckerberg Biohub, San Francisco, CA, USA.
- Center for Human Microbiome Studies, Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Weston R Whitaker, Zachary N Russ, Elizabeth Stanley Shepherd, Alexander Louie, Kathy Lam, David M Zong, Jeanette L Gehrig, Harneet S Rishi, Jessica A Tan, Areta Buness, Sonia Jaidka, Jake Flood, Tariq Warsi, Lachy McLean, Justin L Sonnenburg, William C DeLoache
Förderung
- NIDDK NIH HHS
Zitieren
APA
Whitaker, W. R., Russ, Z. N., Stanley Shepherd, E., Popov, L. M., Louie, A., Lam, K., Zong, D. M., Gill, C. C. C., Gehrig, J. L., Rishi, H. S., Tan, J. A., Buness, A., Godoy, J., Banta, D., Jaidka, S., Wilson, K., Flood, J., Bukshpun, P., Yocum, R., …, & DeLoache, W. C. (2025). Controlled colonization of the human gut with a genetically engineered microbial therapeutic. Science, 389(6757), 303-308. https://doi.org/10.1126/science.adu8000
Vancouver
Whitaker WR, Russ ZN, Stanley Shepherd E, Popov LM, Louie A, Lam K, et al. Controlled colonization of the human gut with a genetically engineered microbial therapeutic. Science. 2025;389(6757):303-308. doi:10.1126/science.adu8000
BibTeX
@article{Whitaker2025,
author = {Whitaker, Weston R and Russ, Zachary N and Stanley Shepherd, Elizabeth and Popov, Lauren M and Louie, Alexander and Lam, Kathy and Zong, David M and Gill, Clare C C and Gehrig, Jeanette L and Rishi, Harneet S and Tan, Jessica A and Buness, Areta and Godoy, Janeth and Banta, Domenique and Jaidka, Sonia and Wilson, Katheryne and Flood, Jake and Bukshpun, Polina and Yocum, Richard and Cook, David N and Warsi, Tariq and McLean, Lachy and Sonnenburg, Justin L and DeLoache, William C},
title = {Controlled colonization of the human gut with a genetically engineered microbial therapeutic},
journal = {Science},
year = {2025},
volume = {389},
number = {6757},
pages = {303--308},
doi = {10.1126/science.adu8000}
}
EUVIMED